Bionet Therapeutics (ROCO:7808) Long-Term Debt: NT$0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7808 Bionet Therapeutics Corp ROCO:7808
20 GF Score
Price NT$33.80
! 2 Warning Signs
View Full Analysis

What is Bionet Therapeutics Long-Term Debt?

Bionet Therapeutics ROCO:7808 +2.42% 20 Long-Term Debt is NT$0.0 Mil as of Jun. 2026. GuruFocus rates ROCO:7808 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Bionet Therapeutics's Long-Term Debt for the quarter that ended in Jun. 2026 was NT$0.0 Mil.

Bionet Therapeutics  (ROCO:7808) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Bionet Therapeutics Long-Term Debt Related Terms

Bionet Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Bionet Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionet Therapeutics Long-Term Debt Chart

Bionet Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Long-Term Debt
0.00 0.00 0.00 0.00

Bionet Therapeutics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Long-Term Debt Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
ROCO:7808
20GF Score
Bionet Therapeutics Corp ROCO:7808
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of NT$0.0 Mil mean?
Bionet Therapeutics (ROCO:7808) has a Long-Term Debt of NT$0.0 Mil as of Jun. 2026.
Is Bionet Therapeutics' Long-Term Debt too high?
Bionet Therapeutics' current Long-Term Debt is NT$0.0 Mil. Overall, Bionet Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Bionet Therapeutics' Long-Term Debt compare to VRTX and REGN?
Bionet Therapeutics' Long-Term Debt of NT$0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Bionet Therapeutics's current Long-Term Debt is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet Therapeutics stock overvalued right now?
Bionet Therapeutics (ROCO:7808) has a current Long-Term Debt of NT$0.0 Mil. The current Long-Term Debt is NT$0.0 Mil. Bionet Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Bionet Therapeutics (ROCO:7808), the current Long-Term Debt is NT$0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bionet Therapeutics Business Description

Address No.28, Lane. 36 , Xinhu 1st Road, 1st Floor, Neihu District, Taipei, TWN, 11497
Bionet Therapeutics Corp is a patient-focused on regenerative medicinal products, R&D, exosomes, and gene/cell therapy biopharmaceutical company. The group develops, manufactures, and provides regenerative medicine preparations and cellular therapies to meet the evolving health needs of people at different stages of life. It focused on treatments that improve patient outcomes. It provides Cell Therapy Products and CRDMO Services.
20GF Score

Get the complete analysis for ROCO:7808

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$33.80
Price